Motexafin gadolinium: a novel radiosensitizer for brain tumors
| Autor: | Dave Francis, Afshin Forouzannia, Gregory M. Richards, Minesh P. Mehta, Deepak Khuntia |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Pharmacology
Oncology Clinical Trials as Topic Radiation-Sensitizing Agents medicine.medical_specialty Radiosensitizer Brain Neoplasms Metalloporphyrins business.industry Antineoplastic Agents General Medicine medicine.disease Combined Modality Therapy chemistry.chemical_compound chemistry Motexafin gadolinium Internal medicine medicine Humans Pharmacology (medical) Cranial Irradiation business Nuclear medicine Brain metastasis Glioblastoma |
| Zdroj: | Expert Opinion on Pharmacotherapy. 10:2171-2180 |
| ISSN: | 1744-7666 1465-6566 |
| DOI: | 10.1517/14656560903179325 |
| Popis: | For a variety of reasons, the management of brain tumors, both primary and metastatic, remains a considerable challenge. As most systemic therapies do not cross the BBB at therapeutic doses, radiation and surgery have played primary roles in the management of these diseases. Despite significant advances in surgical techniques and radiation delivery, outcomes for most adult brain tumors continue to be poor. In an effort to enhance the effects of radiation in the brain, a variety of radiation sensitizers, including motexafin gadolinium, have been investigated. In the following manuscript, we summarize motexafin gadolinium and its role in brain tumors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|